BRPI0920973B8 - composição aquosa contendo hormônio estimulanete de folículos - Google Patents

composição aquosa contendo hormônio estimulanete de folículos

Info

Publication number
BRPI0920973B8
BRPI0920973B8 BRPI0920973A BRPI0920973A BRPI0920973B8 BR PI0920973 B8 BRPI0920973 B8 BR PI0920973B8 BR PI0920973 A BRPI0920973 A BR PI0920973A BR PI0920973 A BRPI0920973 A BR PI0920973A BR PI0920973 B8 BRPI0920973 B8 BR PI0920973B8
Authority
BR
Brazil
Prior art keywords
stimulating hormone
composition containing
aqueous composition
follicle stimulating
containing follicle
Prior art date
Application number
BRPI0920973A
Other languages
English (en)
Inventor
Asada Hajme
Kataoka Hiroshige
Original Assignee
Aska Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharm Co Ltd filed Critical Aska Pharm Co Ltd
Publication of BRPI0920973A2 publication Critical patent/BRPI0920973A2/pt
Publication of BRPI0920973B1 publication Critical patent/BRPI0920973B1/pt
Publication of BRPI0920973B8 publication Critical patent/BRPI0920973B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição aquosa estáveis contendo hormônio estimulador de folículos, que consiste de hormônio estimulador estimulador de folículos e histidina como agente estabilizador.
BRPI0920973A 2008-11-04 2009-11-02 composição aquosa contendo hormônio estimulanete de folículos BRPI0920973B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008283079 2008-11-04
JP2008-283079 2008-11-04
JP2009-216563 2009-09-18
JP2009216563 2009-09-18
PCT/JP2009/005809 WO2010052879A1 (ja) 2008-11-04 2009-11-02 卵胞刺激ホルモン含有水性組成物

Publications (3)

Publication Number Publication Date
BRPI0920973A2 BRPI0920973A2 (pt) 2016-01-05
BRPI0920973B1 BRPI0920973B1 (pt) 2021-02-23
BRPI0920973B8 true BRPI0920973B8 (pt) 2021-05-25

Family

ID=42152693

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920973A BRPI0920973B8 (pt) 2008-11-04 2009-11-02 composição aquosa contendo hormônio estimulanete de folículos

Country Status (13)

Country Link
US (1) US8329649B2 (pt)
EP (1) EP2366401B1 (pt)
JP (1) JP5554244B2 (pt)
KR (1) KR101668502B1 (pt)
CN (1) CN102202682B (pt)
AU (1) AU2009312235B2 (pt)
BR (1) BRPI0920973B8 (pt)
CA (1) CA2742659C (pt)
ES (1) ES2548378T3 (pt)
IL (1) IL212641A (pt)
MX (1) MX2011004453A (pt)
RU (1) RU2561057C2 (pt)
WO (1) WO2010052879A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101668502B1 (ko) * 2008-11-04 2016-10-21 아스카 세이야쿠 가부시키가이샤 난포자극호르몬 함유 수성 조성물
ME02474B (me) 2010-05-12 2017-02-20 Radius Health Inc Terapijski režimi
WO2012145665A2 (en) * 2011-04-22 2012-10-26 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
CN105658201A (zh) * 2013-11-12 2016-06-08 卡迪拉保健有限公司 促性腺激素的制剂
IL297369B1 (en) 2015-04-29 2024-02-01 Radius Pharmaceuticals Inc RAD for use in a method to treat mutant estrogen receptor positive breast cancer or mutant estrogen receptor positive ovarian cancer
KR102322802B1 (ko) 2017-01-05 2021-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
US11643385B2 (en) 2018-07-04 2023-05-09 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl
JP7217364B2 (ja) * 2019-11-29 2023-02-02 千寿製薬株式会社 医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1985644U (de) 1968-01-20 1968-05-22 Broekelmann Jaeger & Busse K G Luesterklemmengehaeuse.
US4114743A (en) 1976-05-03 1978-09-19 Dana Corporation Fluid actuated operator and clutch linkage
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4440679A (en) 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5140010A (en) 1989-09-28 1992-08-18 Immunobiology Research Institute Stabilized aqueous formulations of thymopentin
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
JPH08333277A (ja) 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第xiii因子の安定化された水性液製剤
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
DE19856443A1 (de) 1998-12-08 2000-06-21 Centeon Pharma Gmbh Stabilisiertes Antithrombin III-Präparat
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
AU2001276737A1 (en) 2000-08-04 2002-02-18 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
AR043972A1 (es) 2003-04-02 2005-08-17 Ares Trading Sa Formulaciones farmaceuticas de fsh y lh
ES2358330T5 (es) * 2003-04-02 2018-12-03 Ares Trading S.A. Formulaciones farmacéuticas líquidas de FSH y LH junto con un tensioactivo no iónico
TW200519080A (en) * 2003-10-03 2005-06-16 Ono Pharmaceutical Co Agent containinf (2R)-2-propyloctanic acid as effective component
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
JP4502017B2 (ja) 2008-01-25 2010-07-14 富士ゼロックス株式会社 色材記録装置、色材記録プログラム、及び画像形成装置
KR101668502B1 (ko) * 2008-11-04 2016-10-21 아스카 세이야쿠 가부시키가이샤 난포자극호르몬 함유 수성 조성물

Also Published As

Publication number Publication date
US20110275567A1 (en) 2011-11-10
US8329649B2 (en) 2012-12-11
IL212641A (en) 2013-10-31
AU2009312235B2 (en) 2014-01-16
CA2742659C (en) 2016-09-27
EP2366401B1 (en) 2015-07-15
MX2011004453A (es) 2011-08-12
KR101668502B1 (ko) 2016-10-21
CN102202682A (zh) 2011-09-28
JP5554244B2 (ja) 2014-07-23
BRPI0920973A2 (pt) 2016-01-05
AU2009312235A1 (en) 2011-06-30
ES2548378T3 (es) 2015-10-16
KR20110093812A (ko) 2011-08-18
BRPI0920973B1 (pt) 2021-02-23
EP2366401A1 (en) 2011-09-21
WO2010052879A1 (ja) 2010-05-14
IL212641A0 (en) 2011-07-31
JPWO2010052879A1 (ja) 2012-04-05
EP2366401A4 (en) 2012-08-08
RU2561057C2 (ru) 2015-08-20
RU2011122629A (ru) 2012-12-20
CA2742659A1 (en) 2010-05-14
CN102202682B (zh) 2015-08-19

Similar Documents

Publication Publication Date Title
BRPI0920973B8 (pt) composição aquosa contendo hormônio estimulanete de folículos
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
PE20150200A1 (es) Formulacion de anticuerpos
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
CL2015002519A1 (es) Composiciones antimicrobiales y procedimientos de uso relacionados.
CL2014003509A1 (es) Composición veterinaria masticable blanda que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal (div. sol. n°2087-14).
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
ECSP077299A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CR20110043A (es) Mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas sustituidas
GT201200276A (es) Combinaciones de compuestos activos
CR20120345A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
BR112014029122A2 (pt) composições que compreendem um agente de controle biológico e um inseticida
BR112014029222A2 (pt) composições que compreendem um agente de controle biológico e um inseticida
ECSP11010803A (es) Compuestos de cobre nanoparticulados
BR112014029118A2 (pt) composições que compreendem um agente de controle biológico e um inseticida
BR112015000520A2 (pt) agente de espessamento estável com lipase
EA201071166A1 (ru) Контролируемое высвобождение активных агентов из олеосом
CL2010001620A1 (es) Composicion agricola, del cuidado personal, del cuidado de la casa y de revestimiento que comprende silicona y otro componente adicional; emulsion acuosa y no acuosa que comprende la composicion agricola; y metodo para formular dichas composiciones (div. sol. n° 656-207).
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
BR112015013986A2 (pt) composições de cuidado oral estáveis ao peróxido
DOP2016000007A (es) Pirazolpiridinas sustituidas
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
AR082155A1 (es) Formulacion antiseptica y desinfectante que tiene contenido de yodo reducido
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF